Inhibition of cell proliferation, cytotoxicity and induction of apoptosis of 1,4-bis(1-naphthyl)-2,3-dinitro-1,3-butadiene in gastrointestinal tumour cell lines and preliminary evaluation of its toxicity in vivo

Pharmacological Research

Volumn 52, Issue 3, 2005, Pages 271-282

  Dell'Erba, Carlo ^a   Chiavarina, Barbara ^b   Fenoglio, Carla ^c   Petrillo, Giovanni ^a   Cordazzo, Cinzia ^b   Boncompagni, Eleonora ^c   Spinelli, Domenico ^d   Ognio, Emanuela ^b   Aiello, Cinzia ^b   Mariggiò, Maria A ^e   Viale, Maurizio ^b  

^a UNIVERSITY OF GENOA   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

^c UNIVERSITY OF PAVIA   (Italy)

^d UNIVERSITY OF BOLOGNA   (Italy)

^e UNIVERSITY OF BARI   (Italy)

Author keywords

1,4 bis(1 Naphthyl) 2,3 dinitro 1,3 butadiene; Apoptosis; Gastrointestinal tumour cell lines; Growth inhibition; Toxicity

Indexed keywords

1,4 BIS(1 NAPHTHYL) 2,3 DINITRO 1,3 BUTADIENE; 3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; ALKENE DERIVATIVE; ANTINEOPLASTIC AGENT; FLUOROURACIL; GEMCITABINE; IRINOTECAN; OXALIPLATIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; CYTOTOXICITY; DOSE RESPONSE; DRUG ACTIVITY; FEMALE; GASTROINTESTINAL TUMOR; GLYCOGEN METABOLISM; HISTOCHEMISTRY; HUMAN; HUMAN CELL; IC 50; IRON METABOLISM; LETHAL DOSE; LIVER; MAXIMUM TOLERATED DOSE; MOUSE; NONHUMAN; PANCREAS TUMOR; PRIORITY JOURNAL; SPLEEN; STATISTICAL SIGNIFICANCE; STOMACH TUMOR; TUMOR CELL LINE;

ANIMALS; APOPTOSIS; BUTADIENES; CARCINOMA; CELL LINE, TUMOR; CELL PROLIFERATION; FEMALE; GASTROINTESTINAL NEOPLASMS; HEPATOCYTES; KIDNEY; LETHAL DOSE 50; LIVER; MICE; MICE, INBRED STRAINS; SPLEEN;

EID: 22144435875     PISSN: 10436618     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.phrs.2005.03.011     Document Type: Article

References (24)

1. M. Viale, M. Ottone, B. Chiavarina, M.A. Mariggiò, C. Prevosto, and C. Dell'Erba Preliminary evaluation in vitro of the inhibition of cell proliferation, cytotoxicity and induction of apoptosis by 1,4-bis(1-naphthyl)-2, 3-dinitro-1,3-butadiene Invest New Drug 22 2004 359 367
2. A.L. Thomas, K. O'Byrne, and W.P. Steward Chemotherapy for upper gastrointestinal tumours Postgrad Med J 76 2000 321 327
3. A.V. Schally, K. Szepeshazi, A. Nagy, A.M. Comaru-Schally, and G. Halmos New approaches to therapy of cancers of the stomach, colon and pancreas based on peptide analogs Cell Mol Life Sci 61 2004 1042 1068
4. D.A. Lieberman, and W. Atkin Review article: balancing the ideal versus the practical-considerations of colorectal cancer prevention and screening Aliment Pharmacol Ther 19 Suppl. 1 2004 71 76
5. E. Diaz-Rubio New chemotherapeutic advances in pancreatic, colorectal and gastric cancers Oncologist 9 2004 282 294
6. M.L. Rothenberg, M.J. Moore, M.C. Cripp, J.S. Andersen, R.K. Portenoy, and H.A. Burris III A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer Ann Oncol 7 1996 347 353
7. C.M. Rocha Lima, D. Savarese, H. Bruckner, A. Dudek, J. Eckardt, and J. Hainsworth Irinotecan plus gemcitabine induces both radiographic and CA 19-9 tumour marker responses in patients with previously untreated advanced pancreatic cancer J Clin Oncol 20 2002 1182 1191
8. H. Bleiberg CPT-11 in gastrointestinal cancer Eur J Cancer 35 1999 371 379
9. S. Giacchetti, B. Perpoint, R. Zidani, N. Le Bail, R. Faggiuolo, and C. Focan Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer J Clin Oncol 18 2000 136 147
10. M. Novi, M. Ottone, C. Dell'Erba, F. Barbieri, B. Chiavarina, and M. Maccagno 1,4-bis(1-Naphthyl)-2,3-dinitro-1,3-butadiene a novel anticancer compound effective against tumour cell lines characterized by different mechanisms of resistance Oncol Rep 12 2004 91 96
11. C. Dell'Erba, A. Mele, M. Novi, G. Petrillo, and P. Stagnaro Synthetic exploitation of the ring-opening of 3,4-dinitrothiophene. Access to 1,4-disubstituted 2,3-dinitro-1,3-butadienes and 2,3-butanedione dioximes Tetrahedron 48 1992 4407 4418
12. L. Bianchi, C. Dell'Erba, A. Gabellini, M. Novi, G. Petrillo, and C. Tavani Access to 3-arylmethyl-5-(methylthio)isoxazoles via an initial ring-opening of 2-methylthio-4-nitrothiophene Tetrahedron 58 2002 3379 3385
13. R.F. Hussain, A.M.E. Nouri, and R.T.D. Oliver A new approach for measurement of cytotoxicity using colorimetric assay J Immunol Methods 160 1993 89 96
14. H.A. Burris III, M.J. Moore, J. Andersen, M.R. Green, M.L. Rothenberg, and M.R. Modiano Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial J Clin Oncol 15 1997 2403 2413
15. J.D. Berlin, P. Catalano, J.P. Thomas, J.W. Kugler, D.G. Haller, and A.B. Benson III Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297 J Clin Oncol 20 2002 3270 3275
16. J.H. Klinkenbijl, J. Jeekel, T. Sahmoud, R. van Pel, M.L. Couvreur, and C.H. Veenhof Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group Ann Surg 230 1999 776 784
17. C. Louvet, T. Andre, J.M. Tigaud, E. Gamelin, J.Y. Douillard, and R. Brunet Phase II study of oxaliplatin, fluorouracil, and folinic acid in locally advanced or metastatic gastric cancer patients J Clin Oncol 20 2002 4543 4548
18. L.B. Saltz, J.V. Cox, C. Blanke, L.S. Rosen, L. Fehrenbacher, and M.J. Moore Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group N Engl J Med 343 2000 905 914
19. E. Diaz-Rubio, J. Sastre, A. Zaniboni, R. Labianca, H. Cortes-Funes, and F. de Braud Oxaliplatin as single agent in previously untreated colorectal carcinoma patients: a phase II multicentric study Ann Oncol 9 1998 105 108
20. D. Machover, E. Diaz-Rubio, A. de Gramont, A. Schilf, J.J. Gastiaburu, and S. Brienza Two consecutive phase II studies of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines Ann Oncol 7 1996 95 98
21. J.F.R. Kerr, C.M. Winterford, and B.V. Harmon Apoptosis - its significance in cancer and cancer therapy Cancer 73 1994 2013 2026
22. J.A. Hickman Apoptosis induced by anticancer drugs Cancer Metastasis Rev 11 1992 121 139
23. P. Martinsson, G. Liminga, P. Nygren, and R. Larsson Characteristics of etoposide-induced apoptotic cell death in the U-937 human lymphoma cell line Anticancer Drug 12 2001 699 705
24. R.E. Meyn, L.C. Stephens, N.R. Hunter, and L. Milas Apoptosis in murine tumours treated with chemotherapy agents Anticancer Drug 6 1995 443 450